BACKGROUND: Early identification of those with NAFLD activity score ≥ 4 and significant fibrosis (≥F2) or at-risk metabolic dysfunction-associated steatohepatitis (MASH) is a priority as these patients are at increased risk for disease progression and may benefit from therapies. We developed and validated a highly specific metabolomics-driven score to identify at-risk MASH. METHODS: We included derivation (n = 790) and validation (n = 565) cohorts from international tertiary centers. Patients underwent laboratory assessment and liver biopsy for metabolic dysfunction-associated steatotic liver disease. Based on 12 lipids, body mass index, aspartate aminotransferase, and alanine aminotransferase, the MASEF score was developed to identify at-risk MASH and compared to the FibroScan-AST (FAST) score. We further compared the performance of a FIB-4 + MASEF algorithm to that of FIB-4 + liver stiffness measurements (LSM) by vibration-controlled transient elastography (VCTE). RESULTS: The diagnostic performance of the MASEF score showed an area under the receiver-operating characteristic curve, sensitivity, specificity, and positive and negative predictive values of 0.76 (95% CI 0.72-0.79), 0.69, 0.74, 0.53, and 0.85 in the derivation cohort, and 0.79 (95% CI 0.75-0.83), 0.78, 0.65, 0.48, and 0.88 in the validation cohort, while FibroScan-AST performance in the validation cohort was 0.74 (95% CI 0.68-0.79; p = 0.064), 0.58, 0.79, 0.67, and 0.73, respectively. FIB-4+MASEF showed similar overall performance compared with FIB-4 + LSM by VCTE ( p = 0.69) to identify at-risk MASH. CONCLUSION: MASEF is a promising diagnostic tool for the assessment of at-risk MASH. It could be used alternatively to LSM by VCTE in the algorithm that is currently recommended by several guidance publications.

Biocruces Bizkaia Health Research Institute Barakaldo Spain

Biodonostia Research Institute Donostia University Hospital University of the Basque Country CIBERehd IKERBASQUE Donostia Spain

CIC bioGUNE Basque Research and Technology Alliance Derio Spain

Clinic University Hospital University of Valladolid Valladolid Spain

Department of Biochemistry and Genetics School of Sciences University of Navarra Pamplona Spain

Department of Gastroenterology School of Medicine Pontificia Universidad Católica de Chile Santiago Chile

Department of Physiology Faculty of Medicine and Nursing University of the Basque Country UPV EHU Leioa Spain

Division of Liver Diseases Icahn School of Medicine at Mount Sinai New York City New York USA

General University Hospital and the 1st Faculty of Medicine Charles University Prague Czech Republic

Gregorio Marañón University Hospital Madrid Spain

Houston Methodist Hospital Houston Research Institute Houston Texas USA

Houston Research Institute Houston Texas USA

Karsh Division of Gastroenterology and Hepatology Cedars Sinai Medical Center Los Angeles CA

Marqués de Valdecilla University Hospital Cantabria University IDIVAL Santander Spain

National Institute for the Study of Liver and Gastrointestinal Diseases Madrid Spain

OWL Metabolomics Derio Spain

Pinnacle Clinical Research San Antonio Texas USA

Príncipe de Asturias University Hospital Alcalá University Madrid Spain

Puerta del Hierro University Hospital Madrid Spain

Translational and Clinical Research Institute Faculty of Medical Sciences Newcastle University Newcastle upon Tyne United Kingdom

University of Florida Gainesville Florida USA

Valme University Hospital CIBERehd Seville Spain

Virgen del Rocío University Hospital Sevilla Spain

Virginia Commonwealth University Medical Center Richmond Virginia USA

000      

00000naa a2200000 a 4500

001      

bmc24000163

003      

CZ-PrNML

005      

20240213093008.0

007      

ta

008      

240109s2024 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1097/HEP.0000000000000542 $2 doi

035    __

$a (PubMed)37505221

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Noureddin, Mazen $u Houston Methodist Hospital, Houston Research Institute Houston, Texas, USA $u Houston Research Institute, Houston, Texas, USA $1 https://orcid.org/0000000321272040

245    10

$a Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF) / $c M. Noureddin, E. Truong, R. Mayo, I. Martínez-Arranz, I. Mincholé, JM. Banales, M. Arrese, K. Cusi, MT. Arias-Loste, R. Bruha, M. Romero-Gómez, P. Iruzubieta, R. Aller, J. Ampuero, JL. Calleja, L. Ibañez-Samaniego, P. Aspichueta, A. Martín-Duce, T. Kushner, P. Ortiz, SA. Harrison, QM. Anstee, J. Crespo, JM. Mato, AJ. Sanyal

520    9_

$a BACKGROUND: Early identification of those with NAFLD activity score ≥ 4 and significant fibrosis (≥F2) or at-risk metabolic dysfunction-associated steatohepatitis (MASH) is a priority as these patients are at increased risk for disease progression and may benefit from therapies. We developed and validated a highly specific metabolomics-driven score to identify at-risk MASH. METHODS: We included derivation (n = 790) and validation (n = 565) cohorts from international tertiary centers. Patients underwent laboratory assessment and liver biopsy for metabolic dysfunction-associated steatotic liver disease. Based on 12 lipids, body mass index, aspartate aminotransferase, and alanine aminotransferase, the MASEF score was developed to identify at-risk MASH and compared to the FibroScan-AST (FAST) score. We further compared the performance of a FIB-4 + MASEF algorithm to that of FIB-4 + liver stiffness measurements (LSM) by vibration-controlled transient elastography (VCTE). RESULTS: The diagnostic performance of the MASEF score showed an area under the receiver-operating characteristic curve, sensitivity, specificity, and positive and negative predictive values of 0.76 (95% CI 0.72-0.79), 0.69, 0.74, 0.53, and 0.85 in the derivation cohort, and 0.79 (95% CI 0.75-0.83), 0.78, 0.65, 0.48, and 0.88 in the validation cohort, while FibroScan-AST performance in the validation cohort was 0.74 (95% CI 0.68-0.79; p = 0.064), 0.58, 0.79, 0.67, and 0.73, respectively. FIB-4+MASEF showed similar overall performance compared with FIB-4 + LSM by VCTE ( p = 0.69) to identify at-risk MASH. CONCLUSION: MASEF is a promising diagnostic tool for the assessment of at-risk MASH. It could be used alternatively to LSM by VCTE in the algorithm that is currently recommended by several guidance publications.

650    _2

$a lidé $7 D006801

650    _2

$a játra $x diagnostické zobrazování $x patologie $7 D008099

650    _2

$a jaterní cirhóza $x patologie $7 D008103

650    12

$a nealkoholová steatóza jater $x patologie $7 D065626

650    _2

$a fibróza $7 D005355

650    _2

$a prediktivní hodnota testů $7 D011237

650    12

$a elastografie $7 D054459

650    _2

$a biopsie $x škodlivé účinky $7 D001706

655    _2

$a časopisecké články $7 D016428

700    1_

$a Truong, Emily $u Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA $1 https://orcid.org/0000000291673299

700    1_

$a Mayo, Rebeca $u OWL Metabolomics, Derio, Spain $1 https://orcid.org/0000000197332121

700    1_

$a Martínez-Arranz, Ibon $u OWL Metabolomics, Derio, Spain $1 https://orcid.org/0000000194838426

700    1_

$a Mincholé, Itziar $u OWL Metabolomics, Derio, Spain $1 https://orcid.org/0000000157074359

700    1_

$a Banales, Jesus M $u Biodonostia Research Institute, Donostia University Hospital, University of the Basque Country (UPV-EHU), CIBERehd, IKERBASQUE, Donostia, Spain $u Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain $1 https://orcid.org/0000000252242373

700    1_

$a Arrese, Marco $u Department of Gastroenterology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

700    1_

$a Cusi, Kenneth $u University of Florida, Gainesville, Florida, USA

700    1_

$a Arias-Loste, María Teresa $u Marqués de Valdecilla University Hospital, Cantabria University, IDIVAL, Santander, Spain

700    1_

$a Bruha, Radan $u General University Hospital and the First Faculty of Medicine, Charles University, Prague, Czech Republic

700    1_

$a Romero-Gómez, Manuel $u Valme University Hospital, CIBERehd, Seville, Spain

700    1_

$a Iruzubieta, Paula $u Marqués de Valdecilla University Hospital, Cantabria University, IDIVAL, Santander, Spain $1 https://orcid.org/0000000194761801

700    1_

$a Aller, Rocio $u Clinic University Hospital, University of Valladolid, Valladolid, Spain

700    1_

$a Ampuero, Javier $u Virgen del Rocío University Hospital, Sevilla, Spain

700    1_

$a Calleja, José Luis $u Puerta del Hierro University Hospital, Madrid, Spain $1 https://orcid.org/0000000222656591

700    1_

$a Ibañez-Samaniego, Luis $u Gregorio Marañón University Hospital, Madrid, Spain

700    1_

$a Aspichueta, Patricia $u Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain $u Biocruces Bizkaia Health Research Institute, Barakaldo, Spain $u National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III), Madrid, Spain

700    1_

$a Martín-Duce, Antonio $u Príncipe de Asturias University Hospital, Alcalá University, Madrid, Spain $1 https://orcid.org/0000000187519224

700    1_

$a Kushner, Tatyana $u Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York City, New York, USA

700    1_

$a Ortiz, Pablo $u OWL Metabolomics, Derio, Spain $1 https://orcid.org/0000000226988470

700    1_

$a Harrison, Stephen A $u Pinnacle Clinical Research, San Antonio, Texas, USA

700    1_

$a Anstee, Quentin M $u Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom $1 https://orcid.org/0000000295180088

700    1_

$a Crespo, Javier $u Marqués de Valdecilla University Hospital, Cantabria University, IDIVAL, Santander, Spain $1 https://orcid.org/0000000182480172

700    1_

$a Mato, José M $u National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III), Madrid, Spain $u CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Derio, Spain $1 https://orcid.org/0000000312643153

700    1_

$a Sanyal, Arun J $u Virginia Commonwealth University Medical Center, Richmond, Virginia, USA $1 https://orcid.org/0000000186825748

773    0_

$w MED00009806 $t Hepatology $x 1527-3350 $g Roč. 79, č. 1 (2024), s. 135-148

856    41

$u https://pubmed.ncbi.nlm.nih.gov/37505221 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y - $z 0

990    __

$a 20240109 $b ABA008

991    __

$a 20240213093005 $b ABA008

999    __

$a ok $b bmc $g 2049071 $s 1209857

BAS    __

$a 3

BAS    __

$a PreBMC-MEDLINE

BMC    __

$a 2024 $b 79 $c 1 $d 135-148 $e 20230724 $i 1527-3350 $m Hepatology $n Hepatology $x MED00009806

LZP    __

$a Pubmed-20240109